ANCA at switching to maintenance therapy
|
ANCA-positive
|
1
|
0.004
|
ANCA-negative
|
0.57 (0.38–0.84)
|
ANCA at trial entry
|
MPO-ANCA
|
1
|
0.002
|
PR3-ANCA
|
1.99 (1.30–3.04)
|
Patient age (per decade)
|
0.79 (0.70–0.90)
|
<0.001
|
Serum creatinine at entry (per 50 μmol/L)
|
0.87 (0.80–0.95)
|
0.002
|
Clinical diagnosis
|
GPA
|
1
|
0.002
|
MPA
|
0.72 (0.59–0.89)
|
Initial induction treatment
|
Daily oral cyclophosphamide
|
1
|
0.016
|
Pulsed cyclophosphamide
|
1.64 (1.10–2.45)
|
Initial maintenance therapy
|
AZA
|
1
|
<0.001
|
MMF
|
2.13 (1.42–3.19)
|
Time to remission (per month)
|
1.07 (0.95–1.21)
|
0.279
|